Vascular calcification is frequently found already in early stages of chronic kidney disease (CKD) patients and is associated with high cardiovascular risk. The process of vascular calcification is not considered a passive phenomenon but involves, at least in part, phenotypical transformation of vascular smooth muscle cells (VSMCs). Following exposure to excessive extracellular phosphate concentrations, VSMCs undergo a reprogramming into osteo-/chondroblast-like cells. Such ‘vascular osteoinduction' is characterized by expression of osteogenic transcription factors and triggered by increased phosphate concentrations. A key role in this process is assigned to cellular phosphate transporters, most notably the type III sodium-dependent phosphate transporter Pit1. Pit1 expression is stimulated by mineralocorticoid receptor activation. Therefore, aldosterone participates in the phenotypical transformation of VSMCs. In preclinical models, aldosterone antagonism reduces vascular osteoinduction. Patients with CKD suffer from hyperphosphatemia predisposing to vascular osteogenic transformation, potentially further fostered by concomitant hyperaldosteronism. Clearly, additional research is required to define the role of aldosterone in the regulation of osteogenic signaling and the consecutive vascular calcification in CKD, but more generally also other diseases associated with excessive vascular calcification and even in individuals without overt disease.

Vascular calcification may develop in the common population [1], but may be dramatically accelerated in several clinical disorders, particularly chronic kidney disease (CKD) [2,3,4,5,6,7,8,9,10,11,12,13,14]. Recent observations shed new light on the role of mineralocorticoids in triggering of vascular calcification [6]. The present brief review addresses the role of mineralocorticoids in vascular calcification.

Vascular calcification [15] is not simply the result of passive precipitation of Ca2+ and bivalent phosphate, but results from an active and regulated process involving inhibiting proteins, such as fetuin-A [16] and matrix Gla protein [17], apoptosis of vascular smooth muscle cells (VSMCs) [18,19] and triggering of an osteoinductive signaling cascade transforming VSMCs into osteo- and chondrogenic phenotypes [18,20,21,22,23,24,25,26,27,28,29].

A key role in the phenotypic transformation of VSMCs plays the type III sodium-dependent phosphate transporter Pit1 [30], but the mechanisms linking Pit1 expression to vascular calcification are still incompletely understood [30,31]. The location of the carrier protein may not be confined to the cell membrane and its effect on osteogenic signaling is not necessarily due to phosphate transport across the cell membrane [31]. Pit1 and Pit2 play redundant roles and both may cause phenotypic transformation of VSMCs [32].

The transition of VSMCs into chondroblastic/osteoblastic phenotypes is mediated by key osteogenic transcription factors, most notably by Cbfa1/Runx2 (core-binding factor-α1/runt-related transcription factor 2) [3,5,11]. Cbfa1/Runx2 deficiency inhibits vascular calcification and osteogenesis in the vasculature [11]. The signaling cascade involved in phenotypical transformation of VSMCs involves TNF-α (tumor necrosis factor α) [20], the transcription factors NFκB (nuclear factor-κB) and Msx2 (homeobox protein Hox-8) [33], Wnt (wingless-type MMTV integration site) and β-catenin [3,5,11,34]. This phenotypical change of VSMCs ultimately leads to stimulation of alkaline phosphatase (Alpl) which degrades pyrophosphate, a powerful inhibitor of calcification. Pyrophosphate is generated by ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase) which thus counteracts vascular calcification [31,35]. Pyrophosphate deficiency may contribute to vascular calcification in CKD patients [35].

The vascular calcification/mineral bone disorder is highly prevalent in CKD patients [25,36]. CKD is further associated with reduction of klotho, a cofactor for FGF23, and with increase of FGF23 [37]. Klotho-deficient mice (kl/kl) mimic the vascular calcification of CKD patients [23]. Klotho (i) is required for the inhibition of 1,25 (OH)2D3 formation by FGF23, (ii) modifies the renal tubular transport of calcium and phosphate, and (iii) influences phosphate uptake of VSMCs [23]. In CKD patients, 1,25(OH)2D3 is reduced. Klotho deficiency leads to a marked increase of plasma calcium and phosphate concentrations due to increased 1,25(OH)2D3 formation, which can be blunted by a vitamin D-deficient diet [23,38,39]. The exact role of vitamin D in vascular calcification is still elusive [26,40]. Independently of the mineralocorticoid receptor, spironolactone upregulates klotho via VDR activation [41].

The vascular calcification in kl/kl mice is paralleled by an upregulation of osteogenic signaling (Pit1, TNF-α, Msx2, Cbfa1/Runx2, osterix and Alpl) [23,25,29,38]. The kl/kl mice further suffer from hyperaldosteronism which is partially reversed by a salt-rich diet and a calcium-deficient diet [38]. Presumably, the high extracellular Ca2+ concentration leads in part, via the calcium-sensing receptor in the thick ascending limb, to inhibition of salt reabsorption thus causing extracellular volume depletion and subsequent stimulation of aldosterone secretion [38]. Blocking of mineralocorticoid receptors with spironolactone decreases vascular osteoinduction in the kl/kl mice as apparent by a decline of Pit1, TNF-α, Msx2, Cbfa1/Runx2, osterix and Alpl expression [29].

Whether klotho plays a role in cardiovascular tissue is still incompletely understood. Klotho is not only expressed in the kidney, but in a variety of further cell types including VSMCs [42]. Klotho is required for the vascular effects of FGF23 [42] and interferes with osteoinductive signaling [23]. On the other hand, in a CKD model, neutralization of FGF23 has led to increased phosphate levels and mortality in a CKD model [43]. Dysregulation of the klotho/FGF23 duo presumably plays an important role in CKD [25,36]. In CKD models and CKD patients, aortic klotho expression is reduced [42,44]. Stimulatory effects of FGF23 on vascular calcification have been described [45], but other studies could not show a functional klotho/FGF23 system in vascular tissue [46,47]. Klotho directly influences cardiomyocytes [48] and FGF23 exerts direct effects on the heart independent of klotho [49].

Aldosterone exerts detrimental effects in the cardiovascular system [50]. The mineralocorticoid receptor is expressed in VSMCs and mineralocorticoids stimulate vascular calcification [51,52]. Interestingly, angiotensin II can directly activate the vascular mineralocorticoid receptor [53]. Aldosterone upregulates a wide variety of genes involved in vascular injury and calcification [54]. Accordingly, excessive plasma aldosterone concentrations are associated with vascular stiffening and atherosclerosis [55,56,57]. The development of atherosclerosis is slowed by inhibition of mineralocorticoid receptors [58].

Aldosterone triggers phenotypic reprogramming of smooth muscle cell via TNF-α/Msx2/Cbfa1 signals. These effects of aldosterone are independent of bone morphogenetic protein 2 (BMP2) [51]. Aldosterone causes phenotypic transformation of VSMCs via stimulation of PIT1 [29]. The promoter sequence of the PIT1 gene harbors putative mineralocorticoid response elements MRE/GRE and aldosterone increases the expression of PIT1 in a spironolactone-sensitive manner [29]. Phosphate treatment apparently activates the mineralocorticoid receptor, as spironolactone downregulates PIT1 and CBFA1/RUNX2 gene expression even in the absence of exogenous aldosterone [29]. FGF23 ameliorates the effects of aldosterone on Pit1 expression via klotho [29]. Vascular stiffness is mediated by the mineralocorticoid receptor in smooth muscle cells [59].

The mineralocorticoid receptor is further expressed in endothelial cells where it downregulates the expression of the endothelial NO synthase [60,61]. Aldosterone leads to stiffening of endothelial cells which compromises endothelial cell deformation and subsequent activation of NO synthase [62,63]. This effect is again reversed by spironolactone [64]. Nitric oxide counteracts osteogenic transformation in part by modifying Pai1 expression [24]. Furthermore, aldosterone promotes the generation of oxidative stress and activation of NFκB [54], an effect partially due to upregulation of serum- and glucocorticoid-inducible kinase SGK1 [65]. SGK1 phosphorylates and thus activates the NFκB inhibitory protein IκB kinase IKK, which phosphorylates IκB leading to degradation of IκB and subsequent disinhibition and nuclear translocation of NFκB [65].

In CKD the impaired renal elimination of phosphate [66] leads to increased plasma phosphate concentrations, which trigger detrimental changes in the vasculature [18,22]. Expression of klotho is decreased correlating with enhanced plasma phosphate levels and an unfavorable course of the disease [37]. Markers of osteogenic transformation are found in arteries of CKD patients [18,67]. The vascular calcification leads to vascular events which presumably promote the high mortality of CKD patients [68]. Elevated plasma phosphate levels are associated with a higher risk of death and conversely some studies documented an increased lifespan of CKD patients on phosphate binders [66,69]. Several mechanisms contribute to the phosphate-induced vascular changes [3,21,24,25,28,33] and hyperaldosteronism may be a further contributor to vascular calcification [29,52]. Hyperaldosteronism is frequently found in CKD patients [70,71] so that aldosterone might contribute to enhanced vascular osteoinduction in the vessels of such patients [6].

Recent studies documented a beneficial effect of aldosterone antagonism [50,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98]. In peritoneal dialysis patients, spironolactone treatment showed protective effects on cardiac function [99]. Furthermore, spironolactone treatment showed beneficial effects on endothelial dysfunction in hemodialysis patients without heart failure [100]. Most importantly, there is recent documentation that spironolactone treatment reduced the risk of both cardiovascular morbidity and death in hemodialysis patients [101]. Unfortunately, aldosterone antagonism is associated with the risk of hyperkalemia [102] in patients with and without remaining renal function. In CKD patients, an initial decline of estimated glomerular filtration rate was noted [103]. The occurrence of hyperkalemia is a risk, but occurs only in a low percentage of patients [101,102]. Clearly, further studies are required to assess the risks and benefits of aldosterone antagonism in CKD.

Aldosterone upregulates the type III sodium-dependent phosphate transporter Pit1 and thus contributes to the osteoinductive cascade involved in vascular calcification [29,52]. The effect is reversed by the mineralocorticoid receptor antagonist spironolactone. Spironolactone or other aldosterone antagonists are thus expected to delay the onset of vascular calcification by reducing transdifferentiation of VSMCs into osteo-/chondroblast-like cells. Future analysis will reveal whether mineralocorticoid antagonism can accomplish reduction of vascular calcification without untoward side effects [70].

1.
Greenwald SE: Ageing of the conduit arteries. J Pathol 2007;211:157-172.
2.
An WS, Lee SM, Park TH, Kim SE, Kim KH, Park YJ, Son YK: Association between diastolic dysfunction by color tissue Doppler imaging and vascular calcification on plain radiographs in dialysis patients. Kidney Blood Press Res 2012;35:619-626.
3.
Hofmann Bowman MA, McNally EM: Genetic pathways of vascular calcification. Trends Cardiovasc Med 2012;22:93-98.
4.
Ikee R, Tsunoda M, Sasaki N, Sato N, Hashimoto N: Emerging effects of sevelamer in chronic kidney disease. Kidney Blood Press Res 2013;37:24-32.
5.
Johnson RC, Leopold JA, Loscalzo J: Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006;99:1044-1059.
6.
Lang F, Ritz E, Voelkl J, Alesutan I: Vascular calcification - is aldosterone a culprit? Nephrol Dial Transplant 2013;28:1080-1084.
7.
Lee SY, Kim HY, Gu SW, Kim HJ, Yang DH: 25-Hydroxyvitamin D levels and vascular calcification in predialysis and dialysis patients with chronic kidney disease. Kidney Blood Press Res 2012;35:349-354.
8.
Lucisano S, Buemi M, Passantino A, Aloisi C, Cernaro V, Santoro D: New insights on the role of vitamin D in the progression of renal damage. Kidney Blood Press Res 2013;37:667-678.
9.
Shih CJ, Tarng DC, Yang WC, Yang CY: Parathyroidectomy reduces intradialytic hypotension in hemodialysis patients with secondary hyperparathyroidism. Kidney Blood Press Res 2013;37:323-331.
10.
Staude H, Jeske S, Schmitz K, Warncke G, Fischer DC: Cardiovascular risk and mineral bone disorder in patients with chronic kidney disease. Kidney Blood Press Res 2013;37:68-83.
11.
Sun Y, Byon C, Yuan K, Chen J, Mao X, Heath JM, Javed A, Zhang K, Anderson PG, Chen Y: Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ Res 2012;111:543-552.
12.
Wang C, Jiang L, Feng S, Shi Y, Shen H, Shi X, Wang Z, Zeng Y: Risk factor analysis of calcification in aortic and mitral valves in maintenance peritoneal dialysis patients. Kidney Blood Press Res 2013;37:488-495.
13.
Wu M, Rementer C, Giachelli CM: Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 2013;93:365-373.
14.
Yilmaz M, Unsal A, Oztekin E, Kesmezacar O, Kaptanogullari OH, Eren N: The prevalence of hypertension, valve calcification and left ventricular hypertrophy and geometry in peritoneal dialysis patients. Kidney Blood Press Res 2012;35:431-437.
15.
London GM: Bone-vascular cross-talk. J Nephrol 2012;25:619-625.
16.
Herrmann M, Kinkeldey A, Jahnen-Dechent W: Fetuin-A function in systemic mineral metabolism. Trends Cardiovasc Med 2012;22:197-201.
17.
Lu X, Gao B, Yasui T, Li Y, Liu T, Mao X, Hirose M, Wu Y, Yu D, Zhu Q, Kohri K, Xiao C: Matrix Gla protein is involved in crystal formation in kidney of hyperoxaluric rats. Kidney Blood Press Res 2013;37:15-23.
18.
Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM: Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008;118:1748-1757.
19.
Shroff R, Long DA, Shanahan C: Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol 2013;24:179-189.
20.
Al Aly Z: Vascular calcification in uremia: what is new and where are we going? Adv Chronic Kidney Dis 2008;15:413-419.
21.
Ellam TJ, Chico TJ: Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis 2012;220:310-318.
22.
Giachelli CM: The emerging role of phosphate in vascular calcification. Kidney Int 2009;75:890-897.
23.
Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro-o M, Moe OW: Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011;22:124-136.
24.
Kanno Y, Into T, Lowenstein CJ, Matsushita K: Nitric oxide regulates vascular calcification by interfering with TGF-signalling. Cardiovasc Res 2008;77:221-230.
25.
Kuro-o M: Klotho in health and disease. Curr Opin Nephrol Hypertens 2012;21:362-368.
26.
Lau WL, Leaf EM, Hu MC, Takeno MM, Kuro-o M, Moe OW, Giachelli CM: Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 2012;82:1261-1270.
27.
Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM: Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001;89:1147-1154.
28.
Torres PA, De Broe M: Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. Kidney Int 2012;82:19-25.
29.
Voelkl J, Alesutan I, Leibrock CB, Quintanilla-Martinez L, Kuhn V, Feger M, Mia S, Ahmed MS, Rosenblatt KP, Kuro O, Lang F: Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest 2013;123:812-822.
30.
Li X, Yang HY, Giachelli CM: Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006;98:905-912.
31.
Villa-Bellosta R, Levi M, Sorribas V: Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-α, and Pi. Pflugers Arch 2009;458:1151-1161.
32.
Crouthamel MH, Lau WL, Leaf EM, Chavkin NW, Wallingford MC, Peterson DF, Li X, Liu Y, Chin MT, Levi M, Giachelli CM: Sodium-dependent phosphate cotransporters and phosphate-induced calcification of vascular smooth muscle cells: redundant roles for PiT-1 and PiT-2. Arterioscler Thromb Vasc Biol 2013;33:2625-2632.
33.
Lee HL, Woo KM, Ryoo HM, Baek JH: Tumor necrosis factor-α increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. Biochem Biophys Res Commun 2010;391:1087-1092.
34.
Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA: Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005;115:1210-1220.
35.
O'Neill WC, Sigrist MK, McIntyre CW: Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 2010;25:187-191.
36.
Kuro-o M: Phosphate and klotho. Kidney Int Suppl 2011;S20-S23.
37.
Hu MC, Kuro O, Moe OW: The emerging role of klotho in clinical nephrology. Nephrol Dial Transplant 2012;27:2650-2657.
38.
Fischer SS, Kempe DS, Leibrock CB, Rexhepaj R, Siraskar B, Boini KM, Ackermann TF, Foller M, Hocher B, Rosenblatt KP, Kuro-o M, Lang F: Hyperaldosteronism in klotho-deficient mice. Am J Physiol Renal Physiol 2010;299:F1171-F1177.
39.
Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51.
40.
Ellam T, Hameed A, Ul Haque R, Muthana M, Wilkie M, Francis SE, Chico TJ: Vitamin D deficiency and exogenous vitamin D excess similarly increase diffuse atherosclerotic calcification in apolipoprotein E knockout mice. PLoS One 2014;9:e88767.
41.
Alesutan I, Feger M, Pakladok T, Mia S, Ahmed MS, Voelkl J, Lang F: 25-Hydroxyvitamin D3 1α-hydroxylase-dependent stimulation of renal klotho expression by spironolactone. Kidney Blood Press Res 2013;37:475-487.
42.
Lim K, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder D, Hsiao LL: Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012;125:2243-2255.
43.
Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG: FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012;122:2543-2553.
44.
Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC, Freedman BI, Monier-Faugere MC, Malluche H, Hruska KA: CKD-induced wingless/integration-1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol 2014;25:1760-1773.
45.
Jimbo R, Kawakami-Mori F, Mu S, Hirohama D, Majtan B, Shimizu Y, Yatomi Y, Fukumoto S, Fujita T, Shimosawa T: Fibroblast growth factor-23 accelerates phosphate-induced vascular calcification in the absence of klotho deficiency. Kidney Int 2014;85:1103-1111.
46.
Lindberg K, Olauson H, Amin R, Ponnusamy A, Goetz R, Taylor RF, Mohammadi M, Canfield A, Kublickiene K, Larsson TE: Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One 2013;8:e60658.
47.
Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, Chavkin NW, Rahman M, Wahl P, Amaral AP, Hamano T, Master SR, Nessel L, Chai B, Xie D, Kallem RR, Chen J, Lash JP, Kusek JW, Budoff MJ, Giachelli CM, Wolf M: Chronic Renal Insufficiency Cohort Study I: Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013;83:1159-1168.
48.
Xie J, Cha SK, An SW, Kuro OM, Birnbaumer L, Huang CL: Cardioprotection by klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun 2012;3:1238.
49.
Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408.
50.
McGraw AP, McCurley A, Preston IR, Jaffe IZ: Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications. Curr Atheroscler Rep 2013;15:340.
51.
Jaffe IZ, Tintut Y, Newfell BG, Demer LL, Mendelsohn ME: Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler. Thromb Vasc Biol 2007;27:799-805.
52.
Wu SY, Yu YR, Cai Y, Jia LX, Wang X, Xiao CS, Tang CS, Qi YF: Endogenous aldosterone is involved in vascular calcification in rat. Exp Biol Med (Maywood) 2012;237:31-37.
53.
Jaffe IZ, Mendelsohn ME: Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ Res 2005;96:643-650.
54.
Newfell BG, Iyer LK, Mohammad NN, McGraw AP, Ehsan A, Rosano G, Huang PL, Mendelsohn ME, Jaffe IZ: Aldosterone regulates vascular gene transcription via oxidative stress-dependent and -independent pathways. Arterioscler Thromb Vasc Biol 2011;31:1871-1880.
55.
Cooper JN, Tepper P, Barinas-Mitchell E, Woodard GA, Sutton-Tyrrell K: Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults. Clin Exp Hypertens 2012;34:63-70.
56.
De Rita O, Hackam DG, Spence JD: Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J Cardiol 2012;28:706-711.
57.
Hillaert MA, Lentjes EG, Kemperman H, van der GY, Nathoe HM, Beygui F, Montalescot G, Doevendans PA, Wassink AM, van Belle E: Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol 2012;167:1929-1935.
58.
Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, Horiuchi M: Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006;26:917-921.
59.
Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S, Challande P, Jaffe IZ, Labat C, Lacolley P, Jaisser F: Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension 2014;63:520-526.
60.
Quaschning T, Ruschitzka F, Shaw S, Luscher TF: Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 2001;37:801-805.
61.
Rickard AJ, Morgan J, Chrissobolis S, Miller AA, Sobey CG, Young MJ: Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension 2014;63:1033-1040.
62.
Lang F: Stiff endothelial cell syndrome in vascular inflammation and mineralocorticoid excess. Hypertension 2011;57:146-147.
63.
Oberleithner H: Aldosterone makes human endothelium stiff and vulnerable. Kidney Int 2005;67:1680-1682.
64.
Druppel V, Kusche-Vihrog K, Grossmann C, Gekle M, Kasprzak B, Brand E, Pavenstadt H, Oberleithner H, Kliche K: Long-term application of the aldosterone antagonist spironolactone prevents stiff endothelial cell syndrome. FASEB J 2013;27:3652-3659.
65.
Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V: (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev 2006;86:1151-1178.
66.
Shroff R: Phosphate is a vascular toxin. Pediatr Nephrol 2012;28:583-593.
67.
Koleganova N, Piecha G, Ritz E, Schirmacher P, Muller A, Meyer HP, Gross ML: Arterial calcification in patients with chronic kidney disease. Nephrol Dial Transplant 2009;24:2488-2496.
68.
London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-1740.
69.
Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-2633.
70.
Bomback AS, Klemmer PJ: Mineralocorticoid receptor blockade in chronic kidney disease. Blood Purif 2012;33:119-124.
71.
Hene RJ, Boer P, Koomans HA, Mees EJ: Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982;21:98-101.
72.
Allen LA, Shetterly SM, Peterson PN, Gurwitz JH, Smith DH, Brand DW, Fairclough DL, Rumsfeld JS, Masoudi FA, Magid DJ: Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. Circ Heart Fail 2014;7:43-50.
73.
Bae EH, Kim IJ, Joo SY, Kim EY, Kim CS, Choi JS, Ma SK, Kim SH, Lee JU, Kim SW: Renoprotective effects of sildenafil in DOCA-salt hypertensive rats. Kidney Blood Press Res 2012;36:248-257.
74.
Baker WL, White WB: Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis. Ann Pharmacother 2012;46:889-894.
75.
Bienvenu LA, Reichelt ME, Delbridge LM, Young MJ: Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: a focus on the cardiomyocyte. Clin Sci (Lond) 2013;125:409-421.
76.
Bomback AS, Klemmer PJ: Mineralocorticoid receptor blockade in chronic kidney disease. Blood Purif 2012b;33:119-124.
77.
Chen H, Sun F, Zhong X, Shao Y, Yoshimura A, Liu Y: Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. Kidney Blood Press Res 2013;37:557-566.
78.
Collin M, Niemann F, Jaisser F: Mineralocorticoid receptor modulators: a patent review (2007-2012). Expert Opin Ther Pat 2014;24:177-183.
79.
Funder JW: Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control 2013;6:129-138.
80.
Hammer F, Krane V, Stork S, Roser C, Hofmann K, Pollak N, Allolio B, Wanner C: Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrol Dial Transplant 2014;29:400-405.
81.
Lahmer T, Hermans R, Schmaderer C, Chang J, Stock K, Lutz J, Heemann U, Baumann M: Mineralocorticoid receptor antagonism and aldosterone synthesis inhibition do not improve glomerulosclerosis and renal interstitial fibrosis in a model of chronic kidney allograft injury. Kidney Blood Press Res 2012;35:561-567.
82.
Makowka A, Olejniczak-Fortak M, Nowicki M: A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients - a pilot open label study. Kidney Blood Press Res 2012;36:18-25.
83.
Markowitz M, Messineo F, Coplan NL: Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications. Clin Cardiol 2012;35:605-609.
84.
Mavrakanas TA, Gariani K, Martin PY: Mineralocorticoid receptor blockade in addition to angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Eur J Intern Med 2014;25:173-176.
85.
Piotrowski DW: Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy. J Med Chem 2012;55:7957-7966.
86.
Pitt B: The role of mineralocorticoid receptor antagonists in patients with American College of Cardiology/American Heart Association stage B heart failure. Heart Fail Clin 2012;8:247-253.
87.
Richards AM: Mineralocorticoid receptor antagonists for heart failure. Expert Opin Pharmacother 2011;12:2801-2815.
88.
Ronconi V, Turchi F, Appolloni G, di Tizio V, Boscaro M, Giacchetti G: Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists. Curr Vasc Pharmacol 2012;10:238-246.
89.
Roscioni SS, de Zeeuw D, Bakker SJ, Lambers Heerspink HJ: Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol 2012;8:691-699.
90.
Sato A: Mineralocorticoid receptor antagonists: their use and differentiation in Japan. Hypertens Res 2013;36:185-190.
91.
Seawell MR, Al Darazi F, Farah V, Ramanathan KB, Newman KP, Bhattacharya SK, Weber KT: Mineralocorticoid receptor antagonism confers cardioprotection in heart failure. Curr Heart Fail Rep 2013;10:36-45.
92.
Shavit L, Lifschitz MD, Epstein M: Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 2012;81:955-968.
93.
Talatinian A, Chow SL, Heywood JT: Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure. Pharmacotherapy 2012;32:827-837.
94.
Tylicki L, Lizakowski S, Rutkowski P, Renke M, Sulikowska B, Heleniak Z, Donderski R, Bednarski R, Przybylska M, Manitius J, Rutkowski B: The enhanced renin-angiotensin-aldosterone system pharmacological blockade - which is the best? Kidney Blood Press Res 2012;36:335-343.
95.
Van den Berg TN, Rongen GA, Frohlich GM, Deinum J, Hausenloy DJ, Riksen NP: The cardioprotective effects of mineralocorticoid receptor antagonists. Pharmacol Ther 2014;142:72-87.
96.
Young MJ: Targeting the mineralocorticoid receptor in cardiovascular disease. Expert Opin Ther Targets 2013;17:321-331.
97.
Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, O'Connor CM, Gheorghiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Pina IL, Sabbah HN, Sica DA, Tavazzi L, Pitt B: Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012;33:2782-2795.
98.
Zwadlo C, Bauersachs J: Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications. Curr Opin Pharmacol 2013;13:280-286.
99.
Ito Y, Mizuno M, Suzuki Y, Tamai H, Hiramatsu T, Ohashi H, Ito I, Kasuga H, Horie M, Maruyama S, Yuzawa Y, Matsubara T, Matsuo S, Nagoya Spiro Study Group: Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol 2014;25:1094-1102.
100.
Flevari P, Kalogeropoulou S, Drakou A, Leftheriotis D, Panou F, Lekakis J, Kremastinos D, Vlahakos DV: Spironolactone improves endothelial and cardiac autonomic function in non-heart failure hemodialysis patients. J Hypertens 2013;31:1239-1244.
101.
Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, Yakushigawa T, Sugiyama H, Shimada Y, Nojima Y, Shio N: Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 2014;63:528-536.
102.
Edwards NC, Steeds RP, Chue CD, Stewart PM, Ferro CJ, Townend JN: The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol 2012;73:447-454.
103.
Bianchi S, Bigazzi R, Campese VM: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006;70:2116-2123.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.